Delivering better treatments for neglected patients
![](https://mlo1gfdw4hud.i.optimole.com/7AeXmgQ-cZ5oO5NP/w:auto/h:auto/q:79/https://dndi.org/wp-content/uploads/2019/11/Implementation.png)
DNDi’s objective is to deliver 25 new treatments for neglected patients by 2028.
Since 2003, DNDi has worked with its worldwide network of partners to:
- develop two new chemical entities: fexinidazole, the first all-oral treatment for the two forms of sleeping sickness (T.b. gambiense and T.b. rhodesiense), and ravidasvir, a simple-to-use and affordable treatment for hepatitis C
- develop 10 new treatments from existing molecules and recombining drugs to bring better treatments to patients for malaria, Chagas disease, leishmaniasis, HIV-visceral leishmaniasis co-infection, and paediatric HIV
- initiate GARDP, a not-for-profit research and development organization developing and delivering new or improved antibiotic treatments